RIBOLIFE-B Maintains Stable Share Capital in March; 2.11 Million Pre-IPO Options Remain Unexercised

Bulletin Express04-09

For the month ended 31 March 2026, Suzhou Ribo Life Science Co., Ltd. (RIBOLIFE-B) reported no changes in its authorised, registered or issued share capital. Authorised and issued ordinary H-shares closed the period unchanged at 170.55 million shares, each with a par value of RMB 1, translating into total authorised and issued share capital of RMB 170.55 million.

\n\nThe company confirmed full compliance with Hong Kong Main Board Rule 13.32D(1) regarding minimum public float. The public float threshold—set at 15.61% of issued H-shares at listing—remained satisfied as of 31 March 2026.

\n\nShare-based incentives under the Pre-IPO Share Option Scheme were unchanged. A total of 2.11 million options, carrying an exercise price of RMB 3.70 per share, remained outstanding with no vesting or exercises during the month. The earliest vesting date is 9 January 2028.

\n\nThere were no share repurchases, treasury-share movements, warrant issues, convertible securities, or other equity-related arrangements in March 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1157500309?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-09 17:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1157500309","market":"hk","top_or_hot":-1,"title":"RIBOLIFE-B Maintains Stable Share Capital in March; 2.11 Million Pre-IPO Options Remain Unexercised","media":"Bulletin Express","content":"<p>For the month ended 31 March 2026, Suzhou Ribo Life Science Co., Ltd. (RIBOLIFE-B) reported no changes in its authorised, registered or issued share capital. Authorised and issued ordinary H-shares closed the period unchanged at 170.55 million shares, each with a par value of RMB 1, translating into total authorised and issued share capital of RMB 170.55 million.</p>\n<p>\\n\\nThe company confirmed full compliance with Hong Kong Main Board Rule 13.32D(1) regarding minimum public float. The public float threshold—set at 15.61% of issued H-shares at listing—remained satisfied as of 31 March 2026.</p>\n<p>\\n\\nShare-based incentives under the Pre-IPO Share Option Scheme were unchanged. A total of 2.11 million options, carrying an exercise price of RMB 3.70 per share, remained outstanding with no vesting or exercises during the month. The earliest vesting date is 9 January 2028.</p>\n<p>\\n\\nThere were no share repurchases, treasury-share movements, warrant issues, convertible securities, or other equity-related arrangements in March 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RIBOLIFE-B Maintains Stable Share Capital in March; 2.11 Million Pre-IPO Options Remain Unexercised</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRIBOLIFE-B Maintains Stable Share Capital in March; 2.11 Million Pre-IPO Options Remain Unexercised\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-09 17:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>For the month ended 31 March 2026, Suzhou Ribo Life Science Co., Ltd. (RIBOLIFE-B) reported no changes in its authorised, registered or issued share capital. Authorised and issued ordinary H-shares closed the period unchanged at 170.55 million shares, each with a par value of RMB 1, translating into total authorised and issued share capital of RMB 170.55 million.</p>\n<p>\\n\\nThe company confirmed full compliance with Hong Kong Main Board Rule 13.32D(1) regarding minimum public float. The public float threshold—set at 15.61% of issued H-shares at listing—remained satisfied as of 31 March 2026.</p>\n<p>\\n\\nShare-based incentives under the Pre-IPO Share Option Scheme were unchanged. A total of 2.11 million options, carrying an exercise price of RMB 3.70 per share, remained outstanding with no vesting or exercises during the month. The earliest vesting date is 9 January 2028.</p>\n<p>\\n\\nThere were no share repurchases, treasury-share movements, warrant issues, convertible securities, or other equity-related arrangements in March 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06938","symbol_name":"瑞博生物-B","start_time":0,"source_url":"","article_id":"1157500309","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1157500309","pubTimestamp":1775725511,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"For the month ended 31 March 2026, Suzhou Ribo Life Science Co., Ltd. (RIBOLIFE-B) reported no changes in its authorised, registered or issued share capital. Authorised and issued ordinary H-shares...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06938":"瑞博生物-B"},"translate_title":"Ribolife-B 3月股本保持稳定；211万份首次公开发售前购股权仍未行使","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06938":1},"content_text":"For the month ended 31 March 2026, Suzhou Ribo Life Science Co., Ltd. (RIBOLIFE-B) reported no changes in its authorised, registered or issued share capital. Authorised and issued ordinary H-shares closed the period unchanged at 170.55 million shares, each with a par value of RMB 1, translating into total authorised and issued share capital of RMB 170.55 million.\n\\n\\nThe company confirmed full compliance with Hong Kong Main Board Rule 13.32D(1) regarding minimum public float. The public float threshold—set at 15.61% of issued H-shares at listing—remained satisfied as of 31 March 2026.\n\\n\\nShare-based incentives under the Pre-IPO Share Option Scheme were unchanged. A total of 2.11 million options, carrying an exercise price of RMB 3.70 per share, remained outstanding with no vesting or exercises during the month. The earliest vesting date is 9 January 2028.\n\\n\\nThere were no share repurchases, treasury-share movements, warrant issues, convertible securities, or other equity-related arrangements in March 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1157500309","isCrawlerRequest":true}